Using the dapagliflozin patient identification resource can help practices take a systematic, consistent and efficient approach to identify patients who may be considered for dapagliflozin, in-line with the current licensed indications.

That is a key message from the DDA 2023 conference presentation: Time to improve the management of cardiorenal disease in primary care by Mark Stone, practice pharmacist & partner at the Tamer Valley Practice, Launceston & Tamar Valley PCN, clinical director and DDA Board member.

At the conference, delegates were told that primary care plays a critical role in improving the lives of people living with cardiorenal disease.

• To identify individuals most at risk, the key questions to ask are:
• Which patients are at most risk of cardiorenal disease?
• Which patients could benefit most from dapagliflozin?

To support clinical review, practices were referred to the dapagliflozin patient identification resource.

View the presentation: Time to improve the management of cardiorenal disease in primary care